PDF(Pubmed)
Abstract：
UNASSIGNED: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are crucial for ending the pandemic of coronavirus disease 2019 (COVID-19). Currently, the cumulative effect of booster shots of mRNA vaccines on adverse events is not sufficiently characterized.
UNASSIGNED: A survey-based study on vaccine adverse events was conducted in a Japanese medical institute after the third dose of Pfizer BNT162b2. Adverse events were grouped using network analysis, and a heteroscedastic probit model was built to analyse adverse events.
UNASSIGNED: There were two main clusters of adverse events, systemic and local injection site-associated events. Subject background and the experience of previous vaccine-related adverse events were variably associated with the occurrence and intensity of adverse events following the third dose. Among adverse events, only lymphadenopathy increased prominently following the third dose, while the largest increase in other systemic adverse events occurred generally following the second dose.
UNASSIGNED: The effect of repeated booster vaccines on the frequency and intensity of adverse events differs depending on the kind of adverse event.
UNASSIGNED: A survey-based study on vaccine adverse events was conducted in a Japanese medical institute after the third dose of Pfizer BNT162b2. Adverse events were grouped using network analysis, and a heteroscedastic probit model was built to analyse adverse events.
UNASSIGNED: There were two main clusters of adverse events, systemic and local injection site-associated events. Subject background and the experience of previous vaccine-related adverse events were variably associated with the occurrence and intensity of adverse events following the third dose. Among adverse events, only lymphadenopathy increased prominently following the third dose, while the largest increase in other systemic adverse events occurred generally following the second dose.
UNASSIGNED: The effect of repeated booster vaccines on the frequency and intensity of adverse events differs depending on the kind of adverse event.
摘要：
■针对严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）的疫苗对于结束2019年冠状病毒病（COVID-19）的大流行至关重要。目前,mRNA疫苗加强注射对不良事件的累积效应未得到充分表征.
■在第三剂辉瑞BNT162b2后，在日本一家医学研究所进行了一项基于疫苗不良事件的调查研究。不良事件使用网络分析进行分组，并建立了异方差概率模型来分析不良事件。
■有两个主要的不良事件，全身和局部注射部位相关事件。受试者背景和先前疫苗相关不良事件的经验与第三剂量后不良事件的发生和强度可变相关。在不良事件中，只有淋巴结病在第三次剂量后显著增加，而其他全身性不良事件的最大增加通常发生在第二剂之后。
■重复加强疫苗对不良事件的频率和强度的影响因不良事件的种类而异。
■在第三剂辉瑞BNT162b2后，在日本一家医学研究所进行了一项基于疫苗不良事件的调查研究。不良事件使用网络分析进行分组，并建立了异方差概率模型来分析不良事件。
■有两个主要的不良事件，全身和局部注射部位相关事件。受试者背景和先前疫苗相关不良事件的经验与第三剂量后不良事件的发生和强度可变相关。在不良事件中，只有淋巴结病在第三次剂量后显著增加，而其他全身性不良事件的最大增加通常发生在第二剂之后。
■重复加强疫苗对不良事件的频率和强度的影响因不良事件的种类而异。
